ERBB2 and breast cancer: Seventeen (9.1%) women had HR+/HER2+ disease, 81.2% had a WHO performance status of 0–1, and 80.6% of women had a previous diagnosis of early-stage breast cancer, with 89.3% of those having received adjuvant therapy.